Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Johannes Schetelig; Jennifer Hoek; Stephan Stilgenbauer; Jan Moritz Middeke; Niels Smedegaard Andersen; Christopher P. Fox; Stig Lenhoff; Liisa Volin; Avichai Shimoni; Wilfried Schroyens; Michel van Gelder; Donald Bunjes; Anja van Biezen; Henning Baldauf; Liesbeth C. de Wreede; Olivier Tournilhac; Nicolaus Kröger; Ibrahim Yakoub-Agha; Peter Dreger

doi:10.1038/s41409-020-01013-y

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Johannes Schetelig^*
, Jennifer Hoek
, Stephan Stilgenbauer
, Jan Moritz Middeke
, Niels Smedegaard Andersen
, Christopher P. Fox
, Stig Lenhoff
, Liisa Volin
, Avichai Shimoni
, Wilfried Schroyens
, Michel van Gelder
, Donald Bunjes
, Anja van Biezen
, Henning Baldauf
, Liesbeth C. de Wreede
, Olivier Tournilhac
, Nicolaus Kröger
, Ibrahim Yakoub-Agha
, Peter Dreger

^*Corresponding author for this work

Technische Universität Dresden
DKMS Clinical Trials Office
European Society for Blood and Marrow Transplantation (EBMT)
European Research Initiative on Chronic Lymphocytic Leukemia (ERIC)
EBMT Data Office
Ulm University
University of Copenhagen
Nottingham University Hospitals NHS Trust
Lund University
Helsinki University Hospital
Sheba Medical Center at Tel Hashomer
University of Antwerp
Maastricht University
Leiden University
CHU de Clermont-Ferrand
University of Hamburg
CHU de Lille
Heidelberg University

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English
Pages (from-to)	692-695
Number of pages	4
Journal	Bone Marrow Transplantation
Volume	56
Issue number	3
DOIs	https://doi.org/10.1038/s41409-020-01013-y
State	Published - Mar 2021
Externally published	Yes

Funding

Funders
Hoffmann La-Roche
Gilead Sciences
Janssen Biotech
GlaxoSmithKline Australia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41409-020-01013-y

Cite this

Schetelig, J., Hoek, J., Stilgenbauer, S., Middeke, J. M., Andersen, N. S., Fox, C. P., Lenhoff, S., Volin, L., Shimoni, A., Schroyens, W., van Gelder, M., Bunjes, D., van Biezen, A., Baldauf, H., de Wreede, L. C., Tournilhac, O., Kröger, N., Yakoub-Agha, I., & Dreger, P. (2021). Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. Bone Marrow Transplantation, 56(3), 692-695. https://doi.org/10.1038/s41409-020-01013-y

@article{7483e51d7edf4aac8fd916ac4e62e280,

title = "Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study",

author = "Johannes Schetelig and Jennifer Hoek and Stephan Stilgenbauer and Middeke, \{Jan Moritz\} and Andersen, \{Niels Smedegaard\} and Fox, \{Christopher P.\} and Stig Lenhoff and Liisa Volin and Avichai Shimoni and Wilfried Schroyens and \{van Gelder\}, Michel and Donald Bunjes and \{van Biezen\}, Anja and Henning Baldauf and \{de Wreede\}, \{Liesbeth C.\} and Olivier Tournilhac and Nicolaus Kr{\"o}ger and Ibrahim Yakoub-Agha and Peter Dreger",

note = "Funding Information: Conflict of interest JS—consultancy honoraria from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Molmed; lecture fees from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Novartis; research support from Genzyme, Sanofi, GSK, Novartis, Abbvie. CPF—Speaker/consultancy honoraria and travel support from Janssen. SS—Honoraria for consultancy, Advisory board member, Speaker honoraria, Research grants, Travel support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis. PD—consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. The remaining authors declared no conflict of interest.",

year = "2021",

month = mar,

doi = "10.1038/s41409-020-01013-y",

language = "אנגלית",

volume = "56",

pages = "692--695",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "3",

}

Schetelig, J, Hoek, J, Stilgenbauer, S, Middeke, JM, Andersen, NS, Fox, CP, Lenhoff, S, Volin, L, Shimoni, A, Schroyens, W, van Gelder, M, Bunjes, D, van Biezen, A, Baldauf, H, de Wreede, LC, Tournilhac, O, Kröger, N, Yakoub-Agha, I & Dreger, P 2021, 'Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study', Bone Marrow Transplantation, vol. 56, no. 3, pp. 692-695. https://doi.org/10.1038/s41409-020-01013-y

TY - JOUR

T1 - Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia

T2 - Results of a prospective observational study

AU - Schetelig, Johannes

AU - Hoek, Jennifer

AU - Stilgenbauer, Stephan

AU - Middeke, Jan Moritz

AU - Andersen, Niels Smedegaard

AU - Fox, Christopher P.

AU - Lenhoff, Stig

AU - Volin, Liisa

AU - Shimoni, Avichai

AU - Schroyens, Wilfried

AU - van Gelder, Michel

AU - Bunjes, Donald

AU - van Biezen, Anja

AU - Baldauf, Henning

AU - de Wreede, Liesbeth C.

AU - Tournilhac, Olivier

AU - Kröger, Nicolaus

AU - Yakoub-Agha, Ibrahim

AU - Dreger, Peter

N1 - Funding Information: Conflict of interest JS—consultancy honoraria from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Molmed; lecture fees from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Novartis; research support from Genzyme, Sanofi, GSK, Novartis, Abbvie. CPF—Speaker/consultancy honoraria and travel support from Janssen. SS—Honoraria for consultancy, Advisory board member, Speaker honoraria, Research grants, Travel support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis. PD—consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. The remaining authors declared no conflict of interest.

PY - 2021/3

Y1 - 2021/3

UR - https://www.scopus.com/pages/publications/85089457971

U2 - 10.1038/s41409-020-01013-y

DO - 10.1038/s41409-020-01013-y

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 32801318

AN - SCOPUS:85089457971

SN - 0268-3369

VL - 56

SP - 692

EP - 695

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 3

ER -

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study

Funding

UN SDGs

Access to Document

Other files and links

Cite this